Abstract
2-Arylquinazolin-4(3H)-ones (1-25) were synthesized, and evaluated for their xanthine oxidase inhibitory activity. Significant to moderate activities were exhibited by the compounds 1-3, 7, 9, 13-15, 19-21, and 23 with IC50 between 2.80 - 28.13 µM as compared to the standard allopurinol (IC50 (IC50 = 2.01 ± 0.01 µM). Compounds 4-6, 8, 11-12, 16-18, 22, and 24 demonstrated a weak activity with IC50 values 44.60 - 112.60 µM. Nonetheless, compounds 10 and 25 did not show any activity. Amongst all derivatives, compound 2, containing a C-4´ dimethylamino group, was the most potent inhibitor of the enzyme with an IC50 value comparable to the standard. Kinetics studies on the most active compounds (2, 7, 9, 14, 15, 19, and 20) were conducted in order to determine their modes of inhibition and dissociation constants Ki. Some of the compounds of 2-arylquinazolin-4(3H)-one series were thus identified as potential leads for further studies towards the treatment of hyperuricemia and gout.
Keywords: 2-Arylquinazolin-4(3H)-ones, xanthine oxidase inhibition, uric acid, gout, allopurinol.
Graphical Abstract
Medicinal Chemistry
Title:2-Arylquinazolin-4(3H)-ones: Inhibitory Activities Against Xanthine Oxidase
Volume: 12 Issue: 1
Author(s): Humaira Zafar, Syed M. Saad, Shahnaz Perveen, Arshia, Rizwana Malik, Ajmal Khan, Khalid M. Khan and Muhammad I. Choudhary
Affiliation:
Keywords: 2-Arylquinazolin-4(3H)-ones, xanthine oxidase inhibition, uric acid, gout, allopurinol.
Abstract: 2-Arylquinazolin-4(3H)-ones (1-25) were synthesized, and evaluated for their xanthine oxidase inhibitory activity. Significant to moderate activities were exhibited by the compounds 1-3, 7, 9, 13-15, 19-21, and 23 with IC50 between 2.80 - 28.13 µM as compared to the standard allopurinol (IC50 (IC50 = 2.01 ± 0.01 µM). Compounds 4-6, 8, 11-12, 16-18, 22, and 24 demonstrated a weak activity with IC50 values 44.60 - 112.60 µM. Nonetheless, compounds 10 and 25 did not show any activity. Amongst all derivatives, compound 2, containing a C-4´ dimethylamino group, was the most potent inhibitor of the enzyme with an IC50 value comparable to the standard. Kinetics studies on the most active compounds (2, 7, 9, 14, 15, 19, and 20) were conducted in order to determine their modes of inhibition and dissociation constants Ki. Some of the compounds of 2-arylquinazolin-4(3H)-one series were thus identified as potential leads for further studies towards the treatment of hyperuricemia and gout.
Export Options
About this article
Cite this article as:
Zafar Humaira, M. Saad Syed, Perveen Shahnaz, Arshia , Malik Rizwana, Khan Ajmal, M. Khan Khalid and I. Choudhary Muhammad, 2-Arylquinazolin-4(3H)-ones: Inhibitory Activities Against Xanthine Oxidase, Medicinal Chemistry 2016; 12 (1) . https://dx.doi.org/10.2174/1573406410666150807111336
DOI https://dx.doi.org/10.2174/1573406410666150807111336 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cellular Mechanisms of the Protective Effect of Polyphenols on the Neurovascular Unit in Strokes
Cardiovascular & Hematological Agents in Medicinal Chemistry Sildenafil and Cardioprotection
Current Pharmaceutical Design Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Magnetic Resonance Imaging of Short T2 Relaxation Components in Tissue Using Ultrashort Echo Time (UTE) Pulse Sequences
Current Medical Imaging Bioactive Triterpenic Acids: From Agroforestry Biomass Residues to Promising Therapeutic Tools
Mini-Reviews in Organic Chemistry Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology Plant Sterols and Stanols as Cholesterol-Lowering Ingredients in Functional Foods
Recent Patents on Food, Nutrition & Agriculture Genistein: A Boon for Mitigating Ischemic Stroke
Current Topics in Medicinal Chemistry PPARγ and Early Human Placental Development
Current Medicinal Chemistry Stem Cell Therapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Methionine AminoPeptidase Type-2 Inhibitors Targeting Angiogenesis
Current Topics in Medicinal Chemistry Aligned Biomimetic Scaffolds as a New Tendency in Tissue Engineering
Current Stem Cell Research & Therapy Insulin Resistance in Brain and Possible Therapeutic Approaches
Current Vascular Pharmacology Patent Selections
Recent Patents on Cardiovascular Drug Discovery Synthesis and Biological Activity of Prostaglandin Analogs Containing Heteroatoms in the Cyclopentane Ring
Current Organic Chemistry The L-Type Ca2+ Channel as a Therapeutic Target in Heart Disease
Current Medicinal Chemistry Ammonium Activates Ouabain-Activated Signalling Pathway in Astrocytes: Therapeutic Potential of Ouabain Antagonist
Current Neuropharmacology Drug Targets in Cytomegalovirus Infection
Infectious Disorders - Drug Targets Renal Endothelial Dysfunction in Acute Kidney Ischemia Reperfusion Injury
Cardiovascular & Hematological Disorders-Drug Targets